Genentech and OSI Pharmaceuticals have announced top line results from a phase III study evaluating the combination of Avastin and Tarceva as second-line treatment for advanced non-small cell lung cancer.
The trial did not meet its primary endpoint.
Monday, October 06, 2008
Subscribe to:
Post Comments (Atom)
Posts
0 comments:
Post a Comment